09.18.08
Roger Rush, Ph.D. has been named vice president of preclinical development, Wolfe Laboratories. Dr. Rush has more than 25 years of international experience in pharmaceutical R&D with a focus on preclinical research, development, and program management, particularly in the transition of discovery research candidates to clinical development.
"We're delighted to have Dr. Rush as part of our team," said Janet Wolfe, Ph.D, president of WLI. “His wealth of experience will be a tremendous asset to the company. He will play a critical role in the company as we expand our services and continue to provide clients with the highest quality preclinical services in a timely manner."
Prior to joining the company, Dr. Rush held a number of positions of increasing responsibility with pharmaceutical and biotechnology companies, including department head of drug metabolism at Syntex Research in Europe, and vice president of preclinical sciences at Roche Pharmaceuticals, which involved responsibility for the functions of drug metabolism and pharmacokinetics, toxicology and pathology, and pharmaceutical development. Throughout his career he has contributed to the approval of numerous INDs, CTAs, NDAs and MAA drug registration dossiers.
Dr. Rush participated in the transition of the Syntex Research Centre in Edinburgh into Quintiles Transnational and established that facility as a provider of pharmaceutical R&D services. In his role as business development director he was responsible for the sales and marketing of Quintiles’ preclinical services.
"We're delighted to have Dr. Rush as part of our team," said Janet Wolfe, Ph.D, president of WLI. “His wealth of experience will be a tremendous asset to the company. He will play a critical role in the company as we expand our services and continue to provide clients with the highest quality preclinical services in a timely manner."
Prior to joining the company, Dr. Rush held a number of positions of increasing responsibility with pharmaceutical and biotechnology companies, including department head of drug metabolism at Syntex Research in Europe, and vice president of preclinical sciences at Roche Pharmaceuticals, which involved responsibility for the functions of drug metabolism and pharmacokinetics, toxicology and pathology, and pharmaceutical development. Throughout his career he has contributed to the approval of numerous INDs, CTAs, NDAs and MAA drug registration dossiers.
Dr. Rush participated in the transition of the Syntex Research Centre in Edinburgh into Quintiles Transnational and established that facility as a provider of pharmaceutical R&D services. In his role as business development director he was responsible for the sales and marketing of Quintiles’ preclinical services.